➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Patent: 6,537,988

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,537,988
Title: Synergistic methods and compositions for treating cancer
Abstract:The present invention provides a synergistic method for the treatment of cancer which comprises administering to a mammalian specie in need thereof a synergistically, therapeutically effective amount of: (1) at least agent selected from the group consisting of cytotoxic agents and cytostatic agents, and (2) a compound of formula I ##STR1## or a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition for the synergistic treatment of cancer which comprises at least one agent selected from the group consisting of antiproliferative cytotoxic agents and antiproliferative cytostatic agents, a compound of formula I, and a pharmaceutically acceptable carrier.
Inventor(s): Lee; Francis Y. (Yardley, PA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:09/817,456
Patent Claims:see list of patent claims

Details for Patent 6,537,988

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Bristol-Myers Squibb Company (Princeton, NJ) 2020-03-27 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Bristol-Myers Squibb Company (Princeton, NJ) 2020-03-27 RX Orphan search
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Bristol-Myers Squibb Company (Princeton, NJ) 2020-03-27 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.